vs
EXELIXIS, INC.（EXEL）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.自由现金流更多（$332.4M vs $-139.5M）。过去两年EXELIXIS, INC.的营收复合增速更高（18.7% vs -100.0%）
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
EXEL vs RVMD — 直观对比
营收规模更大
EXEL
是对方的Infinity倍
$0
自由现金流更多
EXEL
多$471.9M
$-139.5M
两年增速更快
EXEL
近两年复合增速
-100.0%
损益表 — Q4 2026 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $598.7M | $0 |
| 净利润 | $244.5M | $-194.6M |
| 毛利率 | 95.6% | — |
| 营业利润率 | 39.3% | — |
| 净利率 | 40.8% | — |
| 营收同比 | 5.6% | — |
| 净利润同比 | 74.8% | -20.4% |
| 每股收益（稀释后） | $0.89 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXELRVMD
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | — | ||
| Q3 25 | $568.3M | — | ||
| Q2 25 | $555.4M | — | ||
| Q1 25 | $566.8M | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $539.5M | $0 | ||
| Q2 24 | $637.2M | $0 |
净利润EXELRVMD
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | — | ||
| Q3 25 | $184.8M | — | ||
| Q2 25 | $159.6M | — | ||
| Q1 25 | $139.9M | — | ||
| Q4 24 | — | $-194.6M | ||
| Q3 24 | $118.0M | $-156.3M | ||
| Q2 24 | $226.1M | $-133.2M |
毛利率EXELRVMD
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
营业利润率EXELRVMD
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | — | ||
| Q3 25 | 37.6% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 28.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 43.3% | — |
净利率EXELRVMD
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 28.7% | — | ||
| Q1 25 | 24.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.9% | — | ||
| Q2 24 | 35.5% | — |
每股收益（稀释后）EXELRVMD
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | — | ||
| Q3 25 | $0.65 | — | ||
| Q2 25 | $0.55 | — | ||
| Q1 25 | $0.47 | — | ||
| Q4 24 | — | $-1.13 | ||
| Q3 24 | $0.40 | $-0.94 | ||
| Q2 24 | $0.77 | $-0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.2B | $2.3B |
| 总资产 | $2.8B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXELRVMD
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B |
股东权益EXELRVMD
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $2.3B | $1.6B | ||
| Q2 24 | $2.1B | $1.6B |
总资产EXELRVMD
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $2.9B | — | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | $3.0B | $1.8B | ||
| Q2 24 | $2.8B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $333.5M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $332.4M | $-139.5M |
| 自由现金流率自由现金流/营收 | 55.5% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 1.36× | — |
| 过去12个月自由现金流最近4个季度 | $875.8M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流EXELRVMD
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | — | ||
| Q3 25 | $49.0M | — | ||
| Q2 25 | $211.4M | — | ||
| Q1 25 | $240.3M | — | ||
| Q4 24 | — | $-138.3M | ||
| Q3 24 | $271.3M | $-130.4M | ||
| Q2 24 | $119.5M | $-128.2M |
自由现金流EXELRVMD
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $208.5M | — | ||
| Q1 25 | $236.3M | — | ||
| Q4 24 | — | $-139.5M | ||
| Q3 24 | $263.1M | $-133.9M | ||
| Q2 24 | $113.0M | $-130.6M |
自由现金流率EXELRVMD
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 41.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 17.7% | — |
资本支出强度EXELRVMD
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | — |
现金转化率EXELRVMD
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
